Immunotherapy before surgery for early-stage liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of liver cancer called hepatocellular carcinoma that can be removed with surgery
- Your cancer has certain high-risk features, like being large, invading blood vessels, or causing high alpha-fetoprotein levels
- You have not had any prior treatment for liver cancer
- You are generally healthy enough for surgery and have good organ function
- You are between 18 and 80 years old and can use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This study tests whether giving a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks tumor growth)—before surgery can improve outcomes for people with early-stage liver cancer (a single tumor 2-5 cm) when the surgery is likely to have a narrow margin. You would receive the drugs for a few weeks before your scheduled surgery, and then have the surgery as planned. This approach may help reduce the chance of the cancer coming back.
This trial tests whether giving an immunotherapy drug called QL1706 before surgery can help lower the risk of liver cancer coming back. It is for people with early-stage liver cancer that is at higher risk of returning, and the goal is to see if this approach is safe and effective.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.